INTRODUCTION
The neural cell adhesion molecule (NCAM) is a heterogeneous glycoprotein which mediates cell-cell and cell-substratum interactions (for reviews, see Edelman and Crossin, 1991; . NCAM is a member of the immunoglobulin superfamily, the product of a single-copy gene, which consists of at least 24 exons (Owens et al., 1987; Small et al., 1987; Santoni et al., 1989; Thompson et al., 1989) . Three major polypeptide classes are found in rat brain: the two transmembrane isoforms NCAM-A (Mr 190000) and NCAM-B (Mr 135000) (Lyles et al., 1984b) , and the glycosylphosphatidylinositol (GPI)-anchored NCAM-C (Mr 115000-110000) (He et al., 1986 (He et al., , 1987 Sadoul et al., 1986) . Transcription, translation and post-translational modifications of NCAM are regulated in a developmental and cell-specific fashion. NCAM binds in a homophilic manner to NCAM (Rutishauser et al., 1982; Moran and Bock, 1988) and in a heterophilic manner to heparin/heparan sulphate (Cole and Glaser, 1986; Nybroe et al., 1989b) , to various collagens (Probstmeier et al., 1989 (Probstmeier et al., , 1992 , and to chondroitin sulphate proteoglycan (Grumet et al., 1993) .
Although most studies on NCAM have focused on membraneassociated NCAM forms, it has, however, long been known that soluble forms of NCAM also exist. Soluble NCAM was demonstrated in cerebrospinal fluid (CSF) by J0rgensen and Bock (1975) , and in cell culture media from retinal cells, astrocytes and neurons (Rutishauser et al., 1976; Nybroe et al., 1989a) and in amniotic fluid and serum NCAM has been demonstrated in the extracellular matrix of striated and smooth muscle and peripheral nerve (Rieger et al., 1985 (Rieger et al., , 1988 Martini and Schachner, 1986; Gulbenkian et al., 1989) . Soluble NCAM polypeptide bands of Mr 190000, 135000 and a duplet band of 115000-110000 have been demonstrated by immunoblotting of supernatant from high speed centrifugation of rat brain homogenate . Similar bands are observed by immunoisolation of radio-iodinated soluble brain NCAM (Bock et al., 1987; Dalseg et al., 1989) and these NCAM forms have been termed NCAM-sl, NCAM-s2 and NCAMs3/s4 respectively ; the duplet NCAM-s3/s4 will in the following text be referred to as NCAM-s3). Dalseg et al. (1989) found that soluble NCAM constitutes 1-2 % of the total amount of NCAM in rat brain and calculated the extracellular concentration in rat brain to vary from 25 to 100 ,ug/ml, depending on the developmental stage. All three soluble NCAM forms are also present in CSF and plasma Linnemann et al., 1993) at a concentration of approx. 1 ,ug/ml (Dalseg et al., 1989) .
NCAM is not the only cell adhesion molecule that exists in both membrane-bound and soluble form. Intercellular adhesion molecule-I (ICAM-1) is a cell-surface glycoprotein of Mr 90000, mediating various cell-cell interactions in the immune system. A soluble counterpart to ICAM-1 of Mr 82000 is released specifically from the surface of melanoma cells by certain cytokines (Becker et al., 1991; Giavazzi et al., 1992) system (Becker et al., 1991) . It has been suggested that soluble ICAM-1 could be derived from alternatively spliced messenger RNA or from membrane-associated ICAM-1 (Rothlein et al., 1991; Giavazzi et al., 1992) ; however, its origin remains to be determined.
The origin of the soluble NCAM polypeptides is only partly elucidated. He et al. (1987) showed that GPI-linked NCAM-C was released into the extracellular milieu from cultured cerebellar cells and glioma cells, and Nybroe et al. (1989a) showed that a 115000-Mr soluble form was derived from NCAM-A and/or NCAM-B of cultured neurons. Thus, NCAM-s3 is an heterogenous population originating from cleaved transmembrane isoforms as well as released GPI-anchored NCAM-C. NCAM-C may, however, not be the only GPI-linked NCAM isoform giving rise to soluble forms; e.g. in mouse muscle cell lines an NCAM form of Mr 155000, released from the membrane by phosphatidylinositol-specific phospholipase C (PI-PLC), has been reported by Moore et al. (1987) . Several observations indicate strong similarity between soluble and membraneassociated NCAM forms: (1) soluble NCAM-s3 has the same Nterminal amino acid sequence as membrane NCAM ; (2) soluble NCAM is polysialylated and a fraction carries the HNK-1 epitope, which is expressed also by a fraction of the transmembrane NCAM isoforms (Bock et al., 1987) ; (3) soluble NCAM polypeptides co-migrate in SDS/PAGE with membrane NCAM polypeptides (Thiery et al., 1977; Dalseg et al., 1989; Andersson et al., 1993) ; (4) a 110000-M, soluble form can be isolated from crude brain membrane preparations after incubation in physiological buffer (Probstmeier et al., 1989) .
The aim of this study was to elucidate the origin and function of soluble NCAM. Our results indicate that intact transmembrane NCAM isoforms are shed from membranes as soluble polypeptides, both with and without attached lipid. Furthermore, soluble NCAM is shown to inhibit binding of NCAM-expressing cells to immobilized NCAM, indicating that soluble NCAM is capable of modulating NCAM-mediated cell behaviour in vivo.
MATERIALS AND METHODS Antibodies
Polyclonal rabbit antibodies raised against human and rat brain NCAM were prepared as described by and Rasmussen et al. (1982) respectively. For immunoblotting experiments rabbit antibodies against rat brain NCAM were affinity purified by retroblotting and characterized as described in Krog et al. (1992) . Polyclonal rabbit antibodies were raised against a fusion protein consisting of /?-galactosidase and the transmembrane and cytoplasmic domains of NCAM encoded by part of exon 16 and the entire exons 17 and 19. This sequence was prepared from a cDNA encoding the human NCAM-B isoform . Briefly NCAM cDNA was cut with restriction enzymes Aatl and BamHI. The fragment obtained by this treatment was subcloned in reading frame into the expression vector pUEX2 (Haymerle et al., 1986) . Induction and purification of the fusion protein were performed as described by Doorbar et al. (1985) . Rabbits were immunized according to Harboe and Ingild (1983) and the antibodies were affinity-purified: rat brain membranes were mixed with antibodies in 0.5 M NaCl at 4°C for 25 min. Membranes were then pelleted and washed once in 0.5 M NaCl. Bound antibodies were eluted with 0.1 M sodium citrate buffer, pH 2.6, containing 0.5 M NaCl and neutralized with NaOH. Before use the antibodies were absorbed with rat liver membranes. The antibody was termed anti-NCAMcyt. For immunofluorescence studies a monoclonal antibody, T199 (CD56) (Dakopatts, Denmark), was used. CD56 is identical to human NCAM-B (Lanier et al., 1989) . All other antibodies used were obtained from Dakopatts.
Cell cultures
Monolayer cultures of fetal neurons were prepared from embryonic day 15-16 rat forebrain as described by Lyles et al. (1984a) . Mixed cultures of neurons and glial cells were prepared according to the same procedure using newborn rat forebrain, and cultured for 10 days in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Paisley, U.K.) containing 10 % fetal-calfserum (FCS). The rat glioma cells BT4Cn and BT4C were obtained from 0. D. Laerum, Bergen, Norway (Laerum et al., 1977) and were grown in DMEM supplemented with 10 % (v/v) FCS.
Transfectlon
BT4Cn cells were transfected using the calcium phosphate coprecipitation method (Sambrook et al., 1989 ) with full-length human NCAM-B cDNA inserted in sense of the eukaryotic expression vector pH/3 APr-1-neo (Gunning et al., 1987) . G418-resistant colonies were isolated by means of cloning cylinders and tested for NCAM expression by immunofluorescence and immunoblotting (see below). Positive cells were subcloned and used for further studies. Three clones termed B2, B6 and B8 were used. Control cells were transfected with the expression vector alone.
Immunofluorescence staining Cells were grown on coverslips, fixed in 20% (v/v) paraformaldehyde for 20 min, and incubated with the monoclonal antibody T199 diluted 1:50 in PBS. After washing in PBS, rhodamine-conjugated rabbit anti-(mouse immunoglobulin) antibodies suspended in PBS were added. The specimens were examined with a Leitz Ortholux microscope equipped with epiillumination.
Preparation of biological materials
Rat brain Wistar rat brain was homogenized in a 1:3 (w/v) ratio in PBS/0.1 mM phenylmethanesulphonyl fluoride (PMSF) 100 units/ml aprotinin and centrifuged for 15 min at 18000g. The resulting supernatant was further centrifuged for 1 or 3 h at 100000 g. The membrane fractions were treated in two different ways: (1) Membrane proteins were extracted by sonication for 2 min in homogenization buffer containing 2 % (v/v) Triton X-100. (2) For the study of protein shedding, membranes were washed by resuspension 1:10 (v/v) in homogenization buffer followed by centrifugation for 15 min at 18000 g. Washings were repeated five times. The washed membranes were then incubated for 2 h at 37°C in homogenization buffer, and the soluble fraction was obtained by an initial centrifugation for 15 min at 18 000 g followed by a centrifugation for 1 or 3 h at 100000 g. In some experiments washed rat brain membranes were frozen at -20°C (to lyse any membrane vesicles), thawed and washed additionally three times, before incubation for 2 h at 37°C as described above.
NCAM-B transfected cells
A confluent monolayer of NCAM-B or control transfected cells were harvested in homogenization buffer, washed once and frozen overnight. Membranes were treated as above.
CSF CSF was collected as described by Dalseg et al. (1989) and in some experiments centrifuged for 1 h at 100 000g.
Enzyme treatment and ('H]ethanolamine labelling PI-PLC treatment
Washed rat brain membranes corresponding to approx. 20 /ig of protein were treated with 0.5 unit of PI-PLC (from Bacillus cereus, Boehringer-Mannheim Biochemica, Mannheim, Germany) in Tris/HCl, pH 7.4, in a total volume of 50 1,d at 37°C for 5 h (1 unit hydrolyses 1 ,umol of phosphatidylinositol/min under the conditions used). Controls were incubated at 4°C or 37°C for 5 h without enzyme. After incubation, membranes and supernatant were separated by centrifugation for 1 h at 100000 g.
Labelling
[3H]Ethanolamine labelling was performed according to He et al. (1987) .
SDS/PAGE and ImmunoblotUng SDS/PAGE was performed on 7.5 % (w/v) polyacrylamide gels according to the method of Laemmli (1970) . Separated proteins were electroblotted on poly(vinylidene difluoride) membrane (Millipore Corporation, Bedford, MA, U.S.A.) which had been activated in methanol. Non-specific binding was blocked by incubation with 2 % (v/v) Tween-20 in washing buffer (50 mM Tris/HCl, pH 10.2/150 mM NaCl/0.l mM PMSF/0.05 % Tween-20). Blots were incubated with rabbit anti-(human NCAM) antibody diluted 1: 1000, affinity-purified rabbit anti-(rat brain NCAM) (see above) or rabbit anti-NCAMcyt diluted 1:500. Before use anti-(human NCAM) and anti-NCAMcyt were absorbed with human keratin (Sigma, St. Louis, MO, U.S.A.) to remove any cytokeratin antibodies which occur naturally in many rabbits. Bound primary antibodies were visualized by incubation with alkaline phosphatase-conjugated pig anti-(rabbit immunoglobulin) antibodies followed by a chromogenic enzyme reaction.
Density-gradient centrifugatlon
The procedure was essentially as described in . Human serum proteins and incubation medium (after centrifugation for 1 h or 3 h at 100000 g) from NCAM-B-transfected cell membranes (see above) were adjusted to a density of 1.005 g/ml and placed on top of a salt solution of 1.21 g/ml. Centrifugation was performed at 200000 g in swinging buckets (Beckman 18-70 ultracentrifuge, SW 60 rotor) at 10°C for 48 h. Serum proteins were identified and localized by fused rocket immunoelectrophoresis (Harboe and Svendsen, 1983 ) using rabbit anti-(total human serum proteins) and anti-(human lowdensity lipoprotein) antibodies. Proteins in the NCAM-containing samples were precipitated using trichloroacetic acid and subjected to immunoblotting using rabbit anti-(human NCAM) antibody as described above.
Cell-binding assay
Microtitre wells (NUNC Immuno Plate Maxisorp) were coated with 0.8 ,ug of purified adult rat brain membrane NCAM (Rasmussen et al., 1982) or BSA (Sigma) in 100 ul of water. Water was removed by evaporation overnight at room temperature. The wells were thereafter washed three times with PBS and incubated for 4 h at 4°C with 0, 0.2, 0.4 or 0.8 jg of purified soluble NCAM in 50 ,ul of PBS in order to allow the soluble NCAM to bind to the immobilized NCAM. Soluble NCAM was affinity-purified from rat brain supernatant as described by and consisted mainly of NCAM-s3. The rat glioma line BT4C was harvested with 2 mM EDTA in PBS and brought into single-cell suspension. Cells (105/50,1 of DMEM) were added to each microtitre well, still containing the 50 ,ul of PBS with various amounts of soluble NCAM, and incubated for 45 min at 37 'C. Unbound cells were removed by three gentle washes with PBS maintained at 4 'C. Attached cells were fixed and stained with 0.2% (w/v) Fast Green (Sigma) and 0.5% (w/v) Crystal Violet (Sigma) in 20 % (v/v) methanol. The amount ofbound cells was determined by measurement ofthe absorbance at 600 nm. The median value of the absorbance measured in three wells was used as an estimate of cell number. In control experiments, up to 40 ,ug of BSA was added per well instead of soluble NCAM. Furthermore, the anti-NCAM antibody column, which was used for purification of soluble NCAM, was loaded with homogenization buffer instead of brain supernatant and eluted. Addition of this 'empty eluate', instead of soluble NCAM, was also used as a control and shown to have no effect.
RESULTS

NCAM release from brain membranes
Membrane NCAM appears by immunoblotting as three major polypeptide classes in brain, NCAM-A, NCAM-B and NCAM-C (Figure 1, lane 1) . Soluble NCAM in supernatants from highspeed centrifuged brain homogenate appeared as three major polypeptide bands, NCAM-sl, NCAM-s2 and NCAM-s3 (Figure 1, lane 2) , with Mr values identical to the three membrane NCAM polypeptide classes. The polypeptide pattern and the amount of soluble NCAM observed in immunoblots were independent of centrifugation time (1 h or 3 h). To examine whether soluble NCAM polypeptides originated from membrane-associated NCAM, washed rat brain membranes were incubated in PBS and NCAM released into the incubation medium was identified by immunoblotting. All three soluble NCAM polypeptide bands were observed (see Figure 1 , lane 3), indicating that they all were released from the membranes. Even after resuspension and incubation of the membranes had been repeated three times, membrane release of NCAM could be demonstrated.
To rule out the possibility that soluble NCAM in the incubation medium simply represented polypeptides trapped in membrane vesicles and released during incubation, washed membranes were frozen, thawed and washed repeatedly. This treatment did not affect the release of soluble NCAM from membranes.
NCAM-sl, NCAM-s2 and NCAM-s3 are also observed in CSF (Figure 1, lane 4) , indicating that these polypeptides do not simply arise from homogenization of the brain or unphysiological treatment of the membranes. To determine whether NCAM in CSF originated from contaminating cells or cell debris, CSF from adult rats was centrifuged at 100000 g for 1 h and compared with untreated CSF. The polypeptide patterns observed were identical and thus independent of whether centrifugation was performed or not. Thus, NCAM-sl, NCAM-s2 and NCAM-s3 exist in an extracellular soluble form in vivo.
GPI-anchorage of NCAM isoforms Demonstration of release of NCAM-sl and NCAM-s2 from membranes raised the question whether these isoforms represented released, but not previously identified, high-Mr GPIlinked NCAM forms in brain. However, treatment of brain membranes with PI-PLC only released NCAM-C [ Figure 2 , compare lanes 3 and 4 (PI-PLC treated) with lanes 1 and 2 (controls)]. Fetal rat neurons express high amounts of 190000-Mr and 135 000-Mr membrane-associated NCAM forms but not NCAM-C when analysed by immunoblotting (Lyles et al., 1984a; Nybroe et al., 1989a) . To examine the presence of high-M, GPI-anchored NCAM, fetal rat neurons were labelled with [3H]ethanolamine; however, no labelling was observed, whereas NCAM-C was easily labelled in a mixed culture of neurons and glial cells expressing this isoform (not shown). In conclusion, even though a GPI-anchored form other than NCAM-C is reported in muscle, NCAM-sl and NCAM-s2 did not seem to be derived from GPI-linked NCAM isoforms in brain.
Demonstration of cytoplasmic and/or transmembrane epiopes In NCAM-sl and NCAM-s2
Since NCAM-sl and NCAM-s2 did not represent GPI-linked isoforms, they might represent shed intact transmembrane forms and thus contain cytoplasmic and transmembrane domains. Therefore, a polyclonal antibody, anti-NCAMcyt, raised against a fusion protein containing the transmembrane and cytoplasmic domains present in both NCAM-A and NCAM-B, was prepared. By immunoblotting, it was shown that anti-NCAMcyt reacted as expected with the two transmembrane isoforms but not with the GPI-linked form (Figure 3, lane 1) . Incubation media from rat brain membranes and CSF were subsequently subjected to immunoblotting using the anti-NCAMcyt antibody. The antibody reacted with NCAM-sl and NCAM-s2 in membrane incubation media (Figure 3 , lane 2) and in CSF (not shown), indicating that both NCAM-sl and NCAM-s2 contained transmembrane and cytoplasmic epitopes and thus probably represent shed intact transmembrane NCAM-A and NCAM-B.
Shedding of soluble NCAM from NCAM-B-transfected cells
To substantiate further the contention that intact transmembrane NCAM is shed from membranes, a simple test system was established. A rat glioma cell line BT4Cn, which does not express NCAM (Andersson et al., 1991) , was transfected with a fulllength cDNA encoding the transmembrane human NCAM-B isoform, and NCAM-B was shown to be expressed on the cell surface by immunofluorescence staining (Figure 4a Association of lipid with soluble transmembrane NCAM Shed transmembrane NCAM forms behaved as soluble molecules as they could not be pelleted by centrifugation at 100000 g for 3 h. To test whether soluble transmembrane NCAM forms were associated with minor membrane fragments when released from the plasma membrane, soluble NCAM shed from NCAM-Btransfected cells (see Figure 5 , lane 2) was subjected to densitygradient ultracentrifugation, in which proteins associated with lipid bilayer fragments will be retrieved in fractions of low density. After ultracentrifugation shed NCAM-B and the 115 000-Mr fragment of NCAM-B were detected in high-density, as well as low-density fractions, indicating that some, but not all, soluble NCAM was associated with lipid ( Figure 6 ). The 115000-Mr Membrane incubation medium from NCAM-B-transfected BT4Cn cells (see Figure 5 , lane 2) and human serum proteins were adjusted to a density of 1.005 g/ml, placed on top of a 1.21 g/ml salt solution and submitted to ultracentrifugation at 200000 g for 48 h. The positions of serum proteins after centrifugation were localized by immunoelectrophoresis using rabbit antibodies raised against total human serum proteins and human low-density lipoprotein respectively. The positions of low-density lipoprotein (LDL) and albumin (ALB) are indicated. The line illustrates the extent of the salt solution densities from bottom (1.21 = 1.21 g/ml) to top (1.0 = 1.005 g/ml) of the tube. The position of NCAM was determined by immunoblofting and is indicated below the line. fragment in the low-density fraction may represent NCAM-B cleaved under or after the centrifugation. The distribution and polypeptide composition of NCAM in the density gradient were independent of whether NCAM was centrifuged for 1 h or 3 h at 100000 g before application to the gradient. The soluble NCAM polypeptides, NCAM-sl, NCAM-s2 and NCAM-s3, were demonstrated in rat brain and CSF and comigrated with the three major membrane forms in SDS/PAGE. The soluble NCAM polypeptides were shown to be continuously released from brain membranes in suspension. NCAM-sl and NCAM-s2 represented shed intact transmembrane forms, as judged from the following evidence: (1) a polyclonal antibody against transmembrane and/or cytoplasmic epitopes of NCAM reacted with NCAM-sl and NCAM-s2, and (2) soluble NCAM with an Mr value identical to NCAM-B was shed from membranes derived from BT4Cn cells transfected with human NCAM-B cDNA. Release of NCAM-B was not a cell-specific phenomenon as it also has been observed from membranes derived from transfected mouse fibroblast L cells (M. Olsen, K. Edvardsen, unpublished work).
The shed transmembrane NCAM isoforms described in this study behaved as soluble molecules since they were found in the supernatant after high-speed centrifugation. However, densitygradient ultracentrifugation indicated that a fraction of the soluble polypeptides were associated with lipid. NCAM may thus be associated with minor membrane fragments attached to the transmembrane domain when shed from the plasma membrane. Presumably the size or composition of the attached membrane fragments do not allow sedimentation during highspeed centrifugation. Non-sedimentable lipid-protein microvesicles have been observed in extracts of beans (Yao et al., 1991) and were shown to be enriched in phospholipid degradation products and therefore differed in lipid composition from the plasma membrane, apparently resulting in the non-sedimentable nature of the vesicles. Whether soluble NCAM without attached lipid is stripped of lipid before or after release from the membrane remains to be determined. Release of proteins containing hydrophobic transmembrane domains has been described previously, e.g. a transmembrane precursor of epidermal growth factor is released from NIH 3T3 cells transfected with cDNA encoding this protein (Mroczkowski et al., 1989) , and a fragment of the amyloid precursor protein, containing part of the extracellular domain and the entire transmembrane and cytoplasmic domain, is shed from PC-12 cells (Baskin et al., 1991) . Several events may result in shedding of transmembrane proteins in vivo, e.g. processes involved in synaptic plasticity, cell death, active cell movement, where proteins adhering to the substratum are left behind, or as a consequence of plasma membrane protein turnover (Black, 1980) . NCAM-s3, which is the quantitatively major soluble polypeptide class, can be generated by cleavage of NCAM-B, but whether it also can be derived from NCAM-A remains to be determined. Furthermore, NCAM-s3 originates from spontaneous or specific release of GPI-linked NCAM-C (Gennarini et al., 1984; He et al., 1986; Sadoul et al., 1986) . Spontaneously released NCAM-C may still be attached to the GPI-anchor, as is indicated by the presence in the extracellular matrix of NCAM susceptible to cleavage by PI-PLC (Theveniau et al., 1991) . Release of GPI anchored NCAM-C and limited proteolysis of transmembrane NCAM with subsequent generation of NCAM-s3 is likely to be regulated in vivo (Ehlers and Riordan, 1991; Theveniau et al., 1992) . No specific regulatory mechanism for release of the low amounts of transmembrane NCAMisoforms can be envisaged at present. Down-regulation of soluble NCAM from the extracellular space may take place via catabolism, or by diffusion into the CSF (Dalseg et al., 1989) . Studies on the origin of soluble NCAM in CSF have not been performed; however, extracellular proteins in brain may be transferred to CSF and NCAM-sl, NCAM-s2 and NCAM-s3 from CSF may thus also originate from released intact or cleaved transmembrane forms and from released GPI-linked NCAM.
Earlier studies have shown that NCAM-expressing rat glioma (Dalseg et al., 1989) . Rieger et al. (1988) detected NCAM in the basal lamina of frog muscle. Addition of NCAM antibodies after denervation resulted in abnormal patterns of re-innervation. Both old synaptic sites and extrasynaptic regions were re-innervated, suggesting that selective adhesivity due to NCAM in the basal lamina at synaptic sites may be decreased in the presence of anti-NCAM antibodies.
Finally soluble NCAM retards collagen type-I fibril formation and increases the diameter of the fibrils formed, indicating that soluble NCAM is able to influence the configuration of extracellular matrix constituents (Probstmeier et al., 1992) .
In conclusion, the present study has elucidated the origin of various soluble NCAM forms, and soluble NCAM was shown to inhibit NCAM-mediated cell binding, suggesting an important role of soluble NCAM in the extracellular space in vivo. 
